|
|
Synageva is a biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics that leverage the unique competitive advantages of our proprietary Synageva Expression Platform (SEP™). Synageva's development programs address specific unmet medical or market needs in several therapeutic areas including oncology, organ dysfunction, autoimmune diseases, and certain rare disorders.
We have generated a diverse pipeline of product candidates that harness the unique benefits of the SEP™:
- Next generation monoclonal antibodies with glycosylation patterns that increase ADCC activity ~10-100 fold (thus increasing potency and potentially efficacy for oncology targets)
- Novel therapeutic proteins for rare diseases without available therapies
- Next generation and follow on cytokines, with certain compounds possessing significantly superior efficacy profiles
|
